News
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Drugs in the Pipeline
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
News
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
News
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
SABCS 2022
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
SABCS 2022
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Drugs in the Pipeline
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
News
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
Clinical Charts
A list of contraindications and drug interactions for HIV medications.
News
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.